Botulinum Toxin Type A
Active ingredient
Sold as Jeuveau · Nuceiva
- Drug class
- -
- Availability
- Prescription only
- Routes
- Intramuscular
- Markets covered
- 3
- Products on record
- 6
- FDA reports (12 mo)
- 1,361
Overview
Botulinum Toxin Type A is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | May 22, 2026 |
| US United States | FDA | 1 | April 28, 2023 |
| EU European Union | EMA | 1 | May 28, 2024 |
GBUnited Kingdom· MHRA
4 products
Uses
NUCEIVA is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.
How to take
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE JEUVEAU is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. JEUVEAU is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients ( 1 )
How to take
EUEuropean Union· EMA
1 product
Uses
NUCEIVA is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.
How to take
Drug interactions
Known interactions involving Botulinum Toxin Type A. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB556810002 · revised May 22, 2026
- [2]FDA DailyMed · 17a914c1-e54b-4b… · revised April 28, 2023 [PDF]
- [3]European Medicines Agency · EMEA/H/C/004587 · revised May 28, 2024
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.